1. Circ Cardiovasc Interv
Erythropoietin in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary InterventionClinical Perspective
by Ilka Ott, Stefanie Schulz, Julinda Mehilli, Stefanie Fichtner, Martin Hadamitzky, Katharina Hoppe, Tareq Ibrahim, Steffan Martinoff, Steffen Massberg, Karl-Ludwig Laugwitz, Josef Dirschinger, Markus Schwaiger, Adnan Kastrati, Albert Schömig, and
Circ Cardiovasc Interv
Volume 3(5):
October 19, 2010
Copyright © American Heart Association, Inc. All rights reserved.

2. Flow diagram of the trial.
Ilka Ott et al. Circ Cardiovasc Interv. 2010;3:
Copyright © American Heart Association, Inc. All rights reserved.

3. Six-month event-free survival (events: death, recurrent MI, infarct-related artery revascularization, and stroke) in the epoetin (closed line) and the placebo group (dotted line).
Six-month event-free survival (events: death, recurrent MI, infarct-related artery revascularization, and stroke) in the epoetin (closed line) and the placebo group (dotted line). HR indicates hazard ratio.
Ilka Ott et al. Circ Cardiovasc Interv. 2010;3:
Copyright © American Heart Association, Inc. All rights reserved.